Category: Therapeutic information by pharmaceutical companies

The Committee for the Expansion of the Medical Health Basket Services has confirmed that starting from 2021, BMS’s (Bristol Myers Squibb) drug will be included

Q. What is fingolimod/Gilenya? A. Gilenya is a once daily oral treatment for relapsing MS. It works by binding to a docking site (sphingosine-1-phosphate receptor,

Background: Maintaining cognitive function in multiple sclerosis is a major concern. It is a priority to identify factors that can help preserve cognition, in addition

Background: Patients with clinically isolated syndrome (CIS) who had early treatment with interferon beta-1b in the BENEFIT trial had significantly better clinical outcomes up to

The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS There are currently no approved disease-modifying therapies

Objective: Determine molecular effect of Vitamin D3 on interferon-beta response in mononuclear cells. Background: Oral vitamin D has additive effects on IFN-b therapy in reducing

Introduction: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years

Data from single-arm extension of head-to-head TRANSFORMS study show sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment

Results of a large randomized trial have shown that the combination interferon beta-1a and Gatiramer Acetate was not more effective than either agent alone on

Abstract: Enhancing quality of life (QoL) is an important objective of disease-modifying therapies in multiple sclerosis (MS). Strategies to substantiate the effect on QoL and